Listen

Press releases

Receive e-mail alerts

Interne link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference
oktober 31, 2018 om 11:00 AM UTC
Interne link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals
oktober 30, 2018 om 10:15 PM UTC
Interne link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals
oktober 29, 2018 om 11:33 AM UTC
Interne link ProQR to Present at the Chardan Genetic Medicines Conference
oktober 02, 2018 om 11:00 AM UTC
Interne link ProQR Announces Presentations at the OTS Annual Meeting
september 24, 2018 om 11:00 AM UTC
Interne link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
september 11, 2018 om 08:01 PM UTC
Interne link ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares
september 07, 2018 om 08:21 AM UTC
Interne link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
september 05, 2018 om 08:01 PM UTC
Interne link ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3
september 05, 2018 om 09:46 AM UTC
Interne link ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial
september 05, 2018 om 08:00 AM UTC
Interne link ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th
augustus 15, 2018 om 11:00 AM UTC
Interne link ProQR Announces Financial Results for the Second Quarter of 2018
augustus 08, 2018 om 11:00 AM UTC
Interne link ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids
augustus 01, 2018 om 11:00 AM UTC
Interne link ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July
juli 12, 2018 om 11:00 AM UTC
Interne link ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa
juni 28, 2018 om 11:00 AM UTC
Interne link ProQR to Present at the JMP Life Sciences Conference
juni 14, 2018 om 11:00 AM UTC
Interne link ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa
juni 12, 2018 om 11:00 AM UTC
Interne link ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference
juni 04, 2018 om 11:00 AM UTC
Interne link ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board
mei 23, 2018 om 11:00 AM UTC
Interne link ProQR Announces Results for the First Quarter of 2018
mei 09, 2018 om 11:00 AM UTC
Interne link ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB
april 30, 2018 om 11:00 AM UTC
Interne link ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO
april 23, 2018 om 11:00 AM UTC
Interne link ProQR Announces Annual Meeting of Shareholders
april 11, 2018 om 11:00 AM UTC
Interne link ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology
april 10, 2018 om 11:00 AM UTC
Interne link ProQR to Present at Two Upcoming Conferences
april 03, 2018 om 11:00 AM UTC

Press releases

Interne link ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference

Interne link ProQR lizenziert weltweite Rechte für Arzneimittelkandidaten für die Augenheilkunde von Ionis Pharmaceuticals

Interne link ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals

Interne link ProQR to Present at the Chardan Genetic Medicines Conference

Interne link ProQR Announces Presentations at the OTS Annual Meeting

Interne link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Interne link ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares

Interne link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Interne link ProQR annonce des résultats intermédiaires positifs pour un essai clinique de phase 1/2 du QR-110 chez des patients souffrant de ACL10 et prévoit de commencer un essai pivot de phase 2/3

Interne link ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial

Interne link ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th

Interne link ProQR Announces Financial Results for the Second Quarter of 2018

Interne link ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids

Interne link ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July

Interne link ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa

Interne link ProQR to Present at the JMP Life Sciences Conference

Interne link ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

Interne link ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference

Interne link ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board

Interne link ProQR Announces Results for the First Quarter of 2018

Interne link ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB

Interne link ProQR Provides Enrollment Update on QR-110 Clinical Trial and Highlights Ophthalmology Presentations at ARVO

Interne link ProQR Announces Annual Meeting of Shareholders

Interne link ProQR Appoints ADAR Expert Dr. Peter A. Beal to Scientific Advisory Board to Focus on Axiomer® RNA A-to-I Editing Technology

Interne link ProQR to Present at Two Upcoming Conferences